|
|
|
| home > white papers > Nanoparticle Tracking Analysis. A Review of Applications and Usage in the Analysis of Exosomes and Microvesicles - NanoSight |
|
|
 WHITE PAPERS |
|
NanoSight
|
|
Nanoparticle Tracking Analysis. A Review of Applications and Usage in the Analysis of Exosomes and Microvesicles
|
|
The study of exosomes and other cell-derived microvesicles is
an area of rapidly growing importance and the subject of intense interest and
research. The previous lack of suitable methods for their detection, analysis,
enumeration and phenotyping is proving to be a significant limitation in these
studies. This mini-review shows the degree to which the technique of
Nanoparticle Tracking Analysis (NTA) is helping to address these problems.
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
3P Biopharmaceuticals receives FDA approval
[Pamplona, September 16th, 2019] 3P Biopharmaceuticals (3P), a leading Contract Development and Manufacturing Organisation (CDMO) specialized in process development and GMP manufacturing of biologics, receives FDA approval after completing the Pre-Approval Inspection (PAI) conducted at the 3P drug substance manufacturing facility.
More info >> |
|
 |
White Papers |
 |
|
Recommendations for Implementing Assessment Criteria Guidelines in Lymphoma and Chronic Lymphocytic Leukemia Clinical Trials
Perceptive Informatics
Standardized assessment criteria are becoming increasingly important in obtaining valid outcomes in oncology clinical trials. While standardized criteria encourage a more uniform approach to assessing clinical trial data, they are often subject to the interpretation of the user. These differences in interpretation, while seemingly minor, can have a major impact on assessments. The most commonly used standardized criteria for lymphoma have been no exception. Differences such as minimum new lesion size, lymph node normalization size requirements, inclusion of extranodal lesions and assessment of organomegaly can have a profound effect on overall response. Additionally, heightened scrutiny of the assessment criteria used in a given protocol can lead to questions about a drug’s efficacy if not applied correctly according to regulators’ interpretation.
More info >> |
|
 |
Industry Events |
 |
Clinical Trials Europe | Partnerships, Outsourcing, Operations & Technology
27 August - 21 November 2019, Barcelona, Spain
On 19-21 November 2019, the clinical trial community's most influential stakeholders will be meeting in Barcelona to discuss the evolving landscape, honing in on what it takes to harness true value from partnerships, outsourcing, operations, technology and early clinical development, for a faster, more efficient route to market.
More info >> |
|
|
|
